Skip to main
GILD

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences (GILD) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 53%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Gilead Sciences is experiencing a positive outlook driven by robust sales growth attributed to higher demand and market share gains, particularly with Biktarvy, which commands 52% of the U.S. market share and has consistently increased since its launch. The company's projections indicate a notable increase in sales, with HIV growth guidance raised to +5% year-over-year, despite anticipated headwinds, reflecting successful lifecycle management strategies. Furthermore, expansion in the oncology sector, including the promising early programs in inflammation and immunology (I&I), positions Gilead to capture additional market share and boost overall revenue in the coming years.

Bears say

Gilead Sciences faces a negative outlook due to declining revenues in key therapeutic areas, with Veklury reporting a significant 60% year-over-year decrease to $277 million, falling short of market expectations and prompting a downward revision in revenue guidance for fiscal year 2025. Additionally, sales from Trodelvy have experienced a slight quarter-over-quarter decline to $357 million, compounded by forecasts predicting a 10% year-over-year drop in revenue from cell therapy in 2025, underscoring competitive challenges in the oncology segment. The overall performance in cell therapies, down 11% year-over-year, further highlights the company's struggles amid increasing competition, contributing to a cautious sentiment regarding Gilead's financial prospects.

Gilead Sciences (GILD) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 53% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gilead Sciences (GILD) Forecast

Analysts have given Gilead Sciences (GILD) a Buy based on their latest research and market trends.

According to 15 analysts, Gilead Sciences (GILD) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $144.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $144.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gilead Sciences (GILD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.